Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dazdotuftide - Tarsier Pharma

Next Previous
Drug Profile

Dazdotuftide - Tarsier Pharma

Alternative Names: Eye disorder therapeutic - Tarsier Pharma; TRS-01; TRS-02

Latest Information Update: 18 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tarsius Pharma
  • Developer Tarsier Pharma
  • Class Anti-inflammatories; Eye disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveitis
  • Phase I/II Ocular inflammation
  • Preclinical Diabetic macular oedema; Diabetic retinopathy; Dry age-related macular degeneration

Most Recent Events

  • 16 Jan 2024 Tarsier Pharma receives an agreement from the US FDA under Special Protocol Assessment for Tarsier-04 phase III trial for TR S01 eye drops for Uveitis
  • 13 Nov 2023 Tarsier Pharma announces successful outcome of a Type C meeting with the US FDA supporting the advancement of TRS 01 eye drop for Uveitis
  • 13 Nov 2023 Tarsier Pharma plans a Tarsier-04 phase III registrational trial of TR S01 for Uveitis in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top